ESMO Events 2026

Meetings | ESMO

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

Below two collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of each meeting:

• ESMO Sarcoma and Rare Cancers Congress 2026

• ESMO Targeted Anticancer Therapies Congress 2026

ESMO Sarcoma and Rare Cancers Congress 2026

The scientific and educational programme will explore the latest advancements in diagnosis, treatment, biology, and molecular classification of rare solid tumours, ensuring a comprehensive update on the evolving landscape of these complex diseases.

Attendees can engage in Abstract-related sessions, educational lectures, Multidisciplinary Tumour Boards, Special Sessions, Guidelines discussions, and dedicated Young Oncologists sessions, all designed to enhance knowledge and foster interactive discussions.

Whether you are a clinician, researcher, healthcare professional, industry expert, or patient advocate, this congress offers a unique opportunity to connect, learn, and contribute to the future of sarcoma and rare cancer care.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Trabectedin–olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group

• Doubting T(h)OMAS: has the era of precision oncology arrived in uterine leiomyosarcoma?

ESMO Open

• Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network

• Expression of antibody–drug conjugate targets in soft tissue sarcomas

Immuno-Oncology and Technology

• The effect of neoadjuvant radiotherapy on immune cell infiltrates in myxofibrosarcoma

ESMO Gastrointestinal Oncology

• Metastatic solid pseudopapillary neoplasms of the pancreas: current treatment status and exploration of endocrine therapy

• Gastrin-releasing peptide receptor expression in gastrointestinal stromal tumours

ESMO Real World Data and Digital Oncology

• Multimodal identification of a rare head and neck cancer patient cohort in the clinical data warehouse of Greater Paris Teaching Hospital

ESMO Rare Cancers

• Health-related quality of life (HRQoL) challenges in patients with epithelioid hemangioendothelioma (EHE): analysis of an ultra-rare cancer

• The European Cooperative Study Group for Paediatric Rare Tumours (EXPeRT group): a model for collaborative research and clinical care in very rare paediatric tumours

• Anaplastic thyroid carcinoma in a pregnant patient: a case report

• Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: a perspective on evidence gaps

• Secondary malignancies and autoimmune diseases in patients with thymoma and thymic carcinoma: experience from a single tertiary center

ESMO affiliated journals

Cancer Treatment Reviews:

• Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG)

• Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action

Lung Cancer

• Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors

ESMO Targeted Anticancer Therapies Congress 2026

The journey of innovation in cancer treatment begins with early drug development. ESMO TAT serves as a dynamic, multi-stakeholder forum, uniting researchers, industry leaders, investors and regulators under one roof to accelerate the delivery of life-changing anticancer therapies to patients.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Progress in Targeting the Untouchables: Emerging Approaches for Hard-to-Drug Cancer Targets

• Is there a future for Trop-2-targeted ADCs in urothelial carcinoma?

ESMO Open

• Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer

• A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers

Immuno-Oncology and Technology

• Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)

• Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma

ESMO Gastrointestinal Oncology

• Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)

• HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study

ESMO Real World Data and Digital Oncology

• How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer

• Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group

ESMO Rare Cancers

• Disulfiram and copper radio-sensitizes chordoma by targeting chordoma cancer stem cells and senescent cells

• Molecular profiling of sacral chordomas through methylation, spatial transcriptomics and multiplexed immunofluorescence

ESMO affiliated journals

The Breast

• Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer

Cancer Treatment Reviews

• Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action

• Targeted therapies in optic pathway gliomas

• Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates

Lung Cancer

• Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials

• Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC

Clinical Lymphoma, Myeloma and Leukemia

• The evolution of CAR T-cell, bispecific antibodies and antibody drug conjugates for the treatment of multiple myeloma

• Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.